4D Molecular Therapeutics (FDMT) Free Cash Flow Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 137.65% |
| 10 | 4D Molecular Therapeutics | 707.87 Mn | 316.98 Mn | - | -42.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.23% |
| Dec 31, 2025 | 151.76% |
| Sep 30, 2025 | -48.89% |
| Jun 30, 2025 | -43.61% |
| Mar 31, 2025 | -60.74% |
| Dec 31, 2024 | -106.57% |
| Sep 30, 2024 | -911.65% |
| Jun 30, 2024 | -43.19% |
| Mar 31, 2024 | -3.04% |
| Dec 31, 2023 | -4.08% |
| Sep 30, 2023 | 76.28% |
| Jun 30, 2023 | 2.75% |
| Mar 31, 2023 | 3.49% |
| Dec 31, 2022 | 19.15% |
| Sep 30, 2022 | 33.00% |
| Jun 30, 2022 | -33.91% |
| Mar 31, 2022 | -93.10% |
| Dec 31, 2021 | -53.91% |
| Sep 30, 2021 | -49.23% |
| Jun 30, 2021 | -154.02% |